AVEO Pharmaceuticals (AVEO) Q1 Loss Narrower Than Expected
Zacks Investment Research | May 05, 2017 03:53AM ET
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) reported a first-quarter 2017 loss of 12 cents per share, narrower than the Zacks Consensus Estimate as well as year-ago loss of 13 cents.
Shares of the company fell more than 3% on Thursday. However, AVEO’s share price movement shows that the stock has outperformed the Zacks classified Medical-Biomedical/Genetics industry year to date. In fact, AVEO has gained 8.9% during this period, compared with industry’s gain of 4.7% during this period.
AVEO does not have any approved products in its portfolio. The company’s top line mainly comprises of collaboration revenues, milestone and other payments. Total collaboration revenue in the first quarter was approximately $2.5 million, compared with $1.2 million in the year-ago quarter.
Quarterly Highlights
Research & development expenses were up 33.2% to about $8 million. However, general and administrative expenses decreased 5.4% year over year to $2.3 million.
Pipeline Updates
AVEO announced that it has completed the first dose cohort , and initiation of enrollment in the second and final dose cohort,of the phase I portion of the company’s phase I/II TiNivo study evaluating tivozanib in combination with Bristol-Myers Squibb’s (NYSE:BMY) Opdivo (nivolumab), in advanced RCC.
In Feb 2017, AVEO announced that its pivotal phase III trial, TIVO-3, to compare lead candidate tivozanib to Bayer’s (OTC:BAYRY) Nexavar in patients with refractory advanced renal cell carcinoma (RCC), has successfully completed the first safety review by Safety Monitoring Committee (SMC).
The company expects to complete enrolment in Jun 2017 ahead of its prior guidance of Aug 2017. A pre-planned futility analysis of the trial is expected around mid 2017, with top-line data expected in the first quarter of 2018.
2017 Guidance
AVEO expects that its present cash resources of $33.4 million will allow the company to fund its planned operations into the second quarter of 2018.
Our Take
The narrower-than-expected loss in the first-quarter 2017 was encouraging. We expect investor focus to remain on TIVO-3 trial for the third-line treatment of patients with refractory RCC. The trial is being conducted to address the overall survival concerns from the TIVO-1 trial.
Get The News You Want
Moreveover, the concerns were identified by the FDA in the complete response letter issued in Jun 2013. The TIVO-3 trial is also intended to support a request for regulatory approval of tivozanib in the U.S. as a third-line treatment and as a first-line treatment for RCC. However, AVEO is heavily dependent on partnerships for pipeline development. Further, any hiccup in development and regulatory process of lead candidate tivozanib will pull down the stock significantly.
We also believe that securing Novartis AG (NYSE:NVS) as a partner for its cachexia candidate, AV-380, represents a huge positive for AVEO.
Zacks Rank & Stock to Consider
AVEO is a Zacks Rank #4 (Sell) stock. You can see .
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple (NASDAQ:AAPL)'s 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs. A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.